Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Shu Fang has a total of 57 co-authors. Here are the top co-authors by number of shared publications:

  • Ditte Caroline Andersen

    Andersen Group, Department of Clinical Biochemistry, Odense University Hospital, Odense, Denmark

    4 shared publications
  • Qiang Shu

    National Clinical Research Center for Child Health, Children’s Hospital, Zhejiang University School of Medicine, Hangzhou, China

    3 shared publications
  • Jens Ahm Sørensen

    Department of reconstructive surgery, Odense University Hospital, Odense, Denmark

    2 shared publications
  • Lars Peter Riber

    Department of Cardiac, Thoracic and Vascular Surgery, Odense University Hospital, Odense, Denmark

    2 shared publications
  • Alexander Høgsted Ahlmann

    Laboratory of Molecular and Cellular Cardiology, Department of Clinical Biochemistry and Pharmacology, Odense University Hospital, J. B. Winsløws Vej 25, 5000 Odense C, Denmark; Institute of Clinical Research, University of Southern Denmark, J. B. Winsløws Vej 19, 5000 Odense C, Denmark

    1 shared publication
  • Alexander Høgsted Ahlmann

    Laboratory of Molecular & Cellular Cardiology, Department of Clinical Biochemistry & Pharmacology, Odense University Hospital, J. B. Winsløws Vej 25, OdenseC 5000, Denmark

    1 shared publication

Latest Publications

  • Open Access

    Macrophage α7nAChR alleviates the inflammation of neonatal necrotizing enterocolitis through mTOR/NLRP3/IL-1β pathway

    by Leiting Shen, Xiaohui Zhong, Haosen Ji, Sisi Yang, Jingyi Jin, Chengjie Lyu, Yichao Ren, Yi Xiao, Yuebai Zhang, Shu Fang, et al.


  • Open Access

    Decellularised Human Umbilical Artery as a Vascular Graft Elicits Minimal Pro-Inflammatory Host Response Ex Vivo and In Vivo

    by Alexander Høgsted Ahlmann, Shu Fang, Sussi Bagge Mortensen, Line Weis Andersen, Pernille Gejl Pedersen, Johanne Juel Callesen, Sara Thornby Bak, Kate Lykke Lambertsen, Ditte Caroline Andersen

    Small diameter (<6 mm) vessel grafts still pose a challenge for scientists worldwide. Decellularised umbilical artery (dUA) remains promising as small diameter tissue engineered vascular graft (TEVG), yet their immunogenicity remains unknown. Herein, we evaluated the host immune responses, with a focus on the innate part, towards human dUA implantation in mice, and confirmed our findings in an ex vivo allogeneic human setup. Overall, we did not observe any differences in the number of circulating white blood cells nor the number of monocytes among three groups of mice (1) dUA patch; (2) Sham; and (3) Mock throughout the study (day −7 to 28). Likewise, we found no difference in systemic inflammatory and anti-inflammatory cytokine levels between groups. However, a massive local remodelling response with M2 macrophages were observed in the dUA at day 28, whereas M1 macrophages were less frequent. Moreover, human monocytes from allogeneic individuals were differentiated into macrophages and exposed to lyophilised dUA to maximize an eventual M1 response. Yet, dUA did not elicit any immediate M1 response as determined by the absence of CCR7 and CXCL10. Together this suggests that human dUA elicits a minimal pro-inflammatory response further supporting its use as a TEVG in an allogeneic setup.


  • Open Access

    Review: Tissue Engineering of Small-Diameter Vascular Grafts and Their In Vivo Evaluation in Large Animals and Humans

    by Shu Fang, Ditte Gry Ellman, Ditte Caroline Andersen

    To date, a wide range of materials, from synthetic to natural or a mixture of these, has been explored, modified, and examined as small-diameter tissue-engineered vascular grafts (SD-TEVGs) for tissue regeneration either in vitro or in vivo. However, very limited success has been achieved due to mechanical failure, thrombogenicity or intimal hyperplasia, and improvements of the SD-TEVG design are thus required. Here, in vivo studies investigating novel and relative long (10 times of the inner diameter) SD-TEVGs in large animal models and humans are identified and discussed, with emphasis on graft outcome based on model- and graft-related conditions. Only a few types of synthetic polymer-based SD-TEVGs have been evaluated in large-animal models and reflect limited success. However, some polymers, such as polycaprolactone (PCL), show favorable biocompatibility and potential to be further modified and improved in the form of hybrid grafts. Natural polymer- and cell-secreted extracellular matrix (ECM)-based SD-TEVGs tested in large animals still fail due to a weak strength or thrombogenicity. Similarly, native ECM-based SD-TEVGs and in-vitro-developed hybrid SD-TEVGs that contain xenogeneic molecules or matrix seem related to a harmful graft outcome. In contrast, allogeneic native ECM-based SD-TEVGs, in-vitro-developed hybrid SD-TEVGs with allogeneic banked human cells or isolated autologous stem cells, and in-body tissue architecture (IBTA)-based SD-TEVGs seem to be promising for the future, since they are suitable in dimension, mechanical strength, biocompatibility, and availability.


  • Small Diameter Polycaprolactone Vascular Grafts are Patent in sheep Carotid Bypass but Require Antithrombotic Therapy

    by Shu Fang, Alexander Høgsted Ahlmann, Louise Langhorn, Kamal Hussein, Jens Ahm Sørensen, Xiaowei Guan, Søren Paludan Sheikh, Lars Peter Riber, Ditte Caroline Andersen

    Background: Polycaprolactone (PCL) scaffolds exhibit high biocompatibility and are attractive as vascular conduits. Materials & methods: PCL tubes were cultivated in bioreactor with human adipose r...


  • Decellularized human umbilical artery: Biocompatibility and in vivo functionality in sheep carotid bypass model

    by Shu Fang, Sara Schødt Riber, Kamal Hussein, Alexander Høgsted Ahlmann, Eva Bang Harvald, Fazal Khan, Hans Christian Beck, Louise Katrine Kjær Weile, Jens Ahm Sørensen, Søren Paludan Sheikh, et al.


  • Open Access

    TRIM22-Mediated Apoptosis is Associated with Bak Oligomerization in Monocytes

    by Chi Chen, DongYan Zhao, Shu Fang, QiXing Chen, BaoLi Cheng, XiangMing Fang, Qiang Shu

    Monocyte apoptosis is a key mechanism that orchestrates host immune responses during sepsis. TRIM22 is constitutively expressed at high levels in monocytes and plays important roles in the antiviral response and inflammation. Overexpression of TRIM22 interferes with the clonogenic growth of monocytic cells, suggesting that TRIM22 may regulate monocyte survival. However, the effect of TRIM22 on monocyte apoptosis remains unknown. In the present report, lipopolysaccharides (LPS)-primed human peripheral blood monocytes expressing higher levels of TRIM22 were more sensitive to apoptosis. This phenomenon was also observed in TRIM22-overexpressing THP-1 monocytes and was associated with the activation of caspase-9 and caspase-3, as well as the increased expression and oligomerization of the pro-apoptotic protein Bak. Similar expression patterns of TRIM22 and Bak were also observed in LPS-primed, apoptotic human peripheral blood monocytes. In addition, the deletion of either the RING domain or the SPRY domain of TRIM22 significantly attenuated TRIM22-mediated monocyte apoptosis and decreased Bak expression and oligomerization. Furthermore, in monocytes from septic patients, TRIM22 levels were down-regulated and positively correlated with Bak levels. Taken together, these results indicate that TRIM22 plays a critical role in monocyte apoptosis by regulating Bak oligomerization and may have a potential function in the pathogenesis of sepsis.


  • High shear stress-induced pulmonary hypertension alleviated by endothelial progenitor cells independent of autophagy

    by Bi-Jun Xu, Jian Chen, Xi Chen, Xi-Wang Liu, Shu Fang, Qiang Shu, Lei Hu, Shan-Shan Shi, Li-Zhong Du, Lin-Hua Tan

    Pulmonary hypertension (PH) is a progressive disease characterized by lung endothelial cell dysfunction and vascular remodeling. Endothelial progenitor cells (EPCs) have been proved to be a potential therapeutic strategy to treat PH. Autophagy has been found to be protective to hypoxia-induced PH. In this study, we applied high shear stress (HSS)-induced PH, and examined whether EPCs confer resistance against HSS-induced PH through autophagy.


  • Reconstruction of a new pulmonary artery in arterial switch operation

    by Bai-Ping Sun, Shu Fang, Ze-Wei Zhang, Fang-Xia Chen, Jian-Hua Li, Ru Lin, Qiang Shu, Jian-Gen Yu

    This study was undertaken to evaluate the new method for the reconstruction of the pulmonary artery in arterial switch operation (ASO). A total of 108 consecutive infants with congenital heart disease were treated with ASO in our department between January 2004 and June 2012. The new pulmonary arterial root was reconstructed with a fresh autologuos pericardium which was clipped pantslike with continuous mattress suture of 6-0 Prolene thread. Patients were reexamined consecutively at 3 and 6 months and 1, 2 and 6 years after discharge. The pulmonary arterial blood velocity was measured by continuous Doppler during systole. The pulmonary flow of healthy children of same age was also measured in the control group. Simplified Bernoulli formula was used to calculate the pressure gradient via the pulmonary artery for determining whether there was pulmonary stenosis. In this series, 96 infants survived after the surgery and 88 were followed up with a mean peirod of (22±4) months. No pulmonary stenosis was detected with the simplified Bernoulli formula. No pulmonary stenosis was detected with the simplified Bernoulli formula.